| pubmed-article:20234353 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20234353 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:20234353 | lifeskim:mentions | umls-concept:C0030193 | lld:lifeskim |
| pubmed-article:20234353 | lifeskim:mentions | umls-concept:C0153690 | lld:lifeskim |
| pubmed-article:20234353 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20234353 | pubmed:dateCreated | 2010-3-31 | lld:pubmed |
| pubmed-article:20234353 | pubmed:abstractText | Bone metastases are the most common cause of cancer-related pain. Radiotherapy is a safe and effective therapy and is well established for such a situation. A fractionation regimen with a short overall treatment time (< or =1 week) would be preferred if it was as effective as longer courses (2-4 weeks). Randomized clinical trials and meta-analyses have demonstrated that single-fraction radiotherapy with 1 x 8 Gy is as effective for pain relief as multi-fraction regimens such as 5 x 4 Gy in 1 week or 10 x 3 Gy in 2 weeks. Re-irradiation for recurrent pain in the irradiated region is required more often after single-fraction radiotherapy than multi-fraction radiotherapy; however, re-irradiation following single-fraction radiotherapy is safe and effective. Thus, 1 x 8 Gy is considered the standard regimen for uncomplicated painful bone metastases without pathological fractures or spinal cord compression. Multi-fraction radiotherapy results in significantly better remineralization of the osteolytic bone than single-fraction radiotherapy. Remineralization is important for preventing or treating pathological fractures. Multi-fraction long-course radiotherapy results in fewer recurrences of spinal-cord compression within the irradiated spinal region. Thus, long-course multi-fraction radiotherapy should be reserved for patients with a relatively favorable survival prognosis. | lld:pubmed |
| pubmed-article:20234353 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20234353 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20234353 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20234353 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20234353 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20234353 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:20234353 | pubmed:issn | 1759-4782 | lld:pubmed |
| pubmed-article:20234353 | pubmed:author | pubmed-author:SchildSteven... | lld:pubmed |
| pubmed-article:20234353 | pubmed:author | pubmed-author:AbrahmJanet... | lld:pubmed |
| pubmed-article:20234353 | pubmed:author | pubmed-author:RadesDirkD | lld:pubmed |
| pubmed-article:20234353 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20234353 | pubmed:volume | 7 | lld:pubmed |
| pubmed-article:20234353 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20234353 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20234353 | pubmed:pagination | 220-9 | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:meshHeading | pubmed-meshheading:20234353... | lld:pubmed |
| pubmed-article:20234353 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20234353 | pubmed:articleTitle | Treatment of painful bone metastases. | lld:pubmed |
| pubmed-article:20234353 | pubmed:affiliation | Department of Radiation Oncology, University of Lubeck, Ratzeburger Allee 160, 23538 Lubeck, Germany. rades.dirk@gmx.net | lld:pubmed |
| pubmed-article:20234353 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20234353 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20234353 | lld:pubmed |
